Clinical trial NCT05158816: Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Official title: Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19: a Single Centre Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19
Keywords: ECMO
Lead sponsor: Jessa Hospital
Sponsor class: OTHER
First posted: 2021-12-15
Enrollment: 295
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All adult COVID-19 patients (\>18 years) admitted to the ICU between 01/02/2020 and 31/07/2021 with a laboratory confirmation of COVID-19 infection with a positive result on polymerase chain reaction (PCR) assays of nasopharyngeal swab samples or bronchoalveolar lavage

Brief summary: Retrospective single center analyses of COVID-19 patients admitted to the ICU between 01/02/2020 and 31/07/2021.

Detailed description: All adults (\>18 years) with acute hypoxaemic respiratory failure due to diagnosed COVID-19 pneumonia and admitted to ICU from 01/02/2020 until 31/07/2021 were included in the study. Following the World Health Organisation (WHO) protocol 19, laboratory confirmation of COVID-19 infection was defined as a positive result on polymerase chain reaction (PCR) assays of nasopharyngeal swab samples or bronchoalveolar lavage. Only laboratory-confirmed patients were included in the analysis.

Additional data collection

Additional collected parameters are listed below and are collected as a standard-of-care in our hospital:

* Demographics: i.e age, gender, BMI
* DNR code
* Comorbidities: smoking, obesity, hypertension, diabetes, cardiovascular disease, respiratory disease, malignancies, renal failure (AKI), liver failure, gastrointestinal disease, neurological conditions, mental state, other
* Symptoms at the time of admission to ICU: i.e fever, body temperature, dyspnoea, headache, diarrhea etc...
* Laboratory results of all standard parameters measured
* Treatment: antiviral agents, antibiotics, etc...
* Complications: shock, heart failure, sepsis, stroke, etc...
* Ventilation: method, PEEP, FiO2, P/F ratio ..

Eligibility criteria: Inclusion Criteria:

* All adult COVID-19 patients (\>18 years) admitted to the ICU between 01/02/2020 and 31/07/2021 with a laboratory confirmation of COVID-19 infection with a positive result on polymerase chain reaction (PCR) assays of nasopharyngeal swab samples or bronchoalveolar lavage

Exclusion Criteria:

* All adult patients admitted for other reasons to the ICU (no COVID-19 pneumonia)

Primary outcomes:
measure: Mortality
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
measure: 3 Months Mortality
timeFrame: 3 months after admission to ICU
measure: acute kidney injury
timeFrame: through study completion, an average of 1 year
measure: continous renal replacement therapy
timeFrame: through study completion, an average of 1 year
measure: Length of stay in hospital
timeFrame: through study completion, an average of 1 year
measure: Length of stay in ICU
timeFrame: during ICU stay
Other outcomes:
measure: Complications
timeFrame: through study completion, an average of 1 year
Locations:
city: Hasselt
country: Belgium
facility: Jessa Hospital
state: Limburg
Study officials:
References: